Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Unknown 8Completed 5Active not recruiting 5Recruiting 3Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Liposarcoma 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1Colorectal Neoplasms 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × eribulin × Clear all
NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
24 enrolled 24 charts
Breast

Triple Negative Breast Neoplasms

NCT05347134 2026-05-08

SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
254 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06382142 2026-04-20

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
418 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

BioNTech SE

Phase 2 Active not recruiting
83 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06519370 2026-01-22

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
350 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡